Covishield Case: Bereaved parents to take Serum Institute of India to Court following AstraZeneca's rare side effect admission

economictimes.indiatimes.com:

Serum Institute of India (SII), a day after AstraZeneca, which sold the vaccine in India, admitted in court that their Covid shot can cause a rare side effect. The parents are hopeful of justice after the AstraZeneca's admission surfaced. The pharmaceutical giant is being sued in a class-action suit over claims that its Covid-19 vaccine, developed with the University of Oxford, caused death and serious injury, including TTS — thrombosis with thrombocytopenia syndrome — a serious adverse event that causes blood clots and a low blood platelet count.
Venugopalan Govindan, father of Karunya, who died after taking the vaccine, said the admission by AstraZeneca is «too late» and has come after so many lives have been lost. «AstraZeneca and SII should have stopped the manufacture and supply of these vaccines when 15 European countries either suspended or age-limited these due to deaths from blood clots that happened in March 2021, within a couple of months of the rollout of the vaccine itself.»

The parents have filed a writ petition seeking compensation, appointment of an expert medical board independent of the government to forthwith inquire into and investigate the deaths of their daughter, and to share the report of the investigation with them.
When asked, SII said they «won't be commenting on this matter».

AstraZeneca acknowledges its covid vaccine, Covishield, can lead to rare blood clot side effects; Here's what we know

Covishield Side Effects: What's TTS syndrome, symptoms, and danger